Syngenis takes 33% stake in precision-medicine venture Gene S Dx

For health systems and clinicians, the formation of Gene S Dx is not just a corporate restructure. It places an Australian-developed pharmacogenomics platform, Rosa, under a vehicle with laboratory and manufacturing support, potentially making genetic-guided prescribing more accessible in everyday care. The next challenge will be integrating those insights into clinical workflows and reimbursement models.

Perth-based life sciences company Syngenis Labs has formed a new precision-medicine venture called Gene S Dx with the renowned Perron Institute and the scientists behind Gene S, a move that gives Syngenis an additional commercial vehicle in pharmacogenomics. Under the deal announced on 23 September 2026, Syngenis will hold one-third of Gene S Dx through its wholly owned Syngenis Ventures arm. The Perron Institute and Gene S founders Dr Svetlana Baltic and Dr Suzanna Lindsey-Temple will collectively hold a further third. Gene S Dx has acquired the Gene S business, its Rosa pharmacogenomics platform, and the development intellectual property behind it. Syngenis Labs has also made an investment in Gene S Dx to support the platform's growth.

“

The Perron Institute and Gene S founders Dr Svetlana Baltic and Dr Suzanna Lindsey-Temple will collectively hold a further third.

Pharmacogenomics uses a patient's genetic make-up to help determine which medicines and doses may work best for them. The field has become a practical bridge between genomics and everyday prescribing, but commercial success depends on reliable testing, laboratory capacity, and manufacturing quality. Rosa is an Australian-developed pharmacogenomics platform, and placing it inside Gene S Dx gives it a dedicated commercial home. Syngenis brings more than capital: it brings DNA and RNA expertise, laboratory infrastructure, and manufacturing capability that can be deployed to produce the oligonucleotide components used in Rosa's DNA test kits.

For Syngenis, the transaction fits the integrated biotechnology model the Perth group has been building. The company is assembling an Australian end-to-end genetic medicine platform spanning AI-assisted discovery, laboratory development, and ultimately GMP-regulated manufacturing. At the centre of that model are oligonucleotides, short strands of DNA or RNA used in genetic testing and in medicines designed to target or silence disease-related genetic instructions. Syngenis says it can use its Discovery AI platform to identify and design prospective candidates, then synthesise and test them in its own laboratories. With Gene S now under the Gene S Dx umbrella, Syngenis can apply its nucleic-acid chemistry and laboratory expertise to Rosa and manufacture the oligonucleotide components of its DNA test kits in Australia. That is intended to keep more of the genetic-medicine value chain on home soil.

The operational foundation is already being laid. Syngenis' research-grade manufacturing operation at Bentley Technology Park in Perth is already generating revenue, while clinical-grade GMP manufacturing is reportedly being developed. That clinical-grade step is important because regulated manufacturing is a major hurdle for diagnostic and therapeutic supply chains. If Gene S Dx can use Syngenis' existing and future GMP capability, it may reduce reliance on overseas kit production and shorten turnaround times for Australian providers.